Disparities in Medication Use for Criminal Justice System –Referred Opioid Use Disorder Treatment

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.2807?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090624

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

COVID-19 and Rates of Cancer Diagnosis in the US

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, SEPTEMBER 6, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.32288?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This population-based cross-sectional study of U.S. cancer incidence trends found that rates of diagnosis improved in 2021 but continued to be lower than expected, adding to the existing deficit of diagnosed cases from 2020. Particular attention should be directed at strategies to immediately increase cancer screenings to make up lost ground. 

Corresponding Author: To contact the corresponding author, Krystle A. Lang Kuhs, PhD, MPH, email krystle.kuhs@uky.edu.

 

(doi:10.1001/jamanetworkopen.2024.32288)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Cannabis Laws and Utilization of Medications for the Treatment of Mental Health Disorders

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 5, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.32021?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=090524

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cross-sectional study of commercially insured patients suggests that there may have been meaningful heterogeneous associations between cannabis policy and state and between cannabis policy and drug class (e.g., decreases in dispensing of benzodiazepines but increases in dispensing of antidepressants and antipsychotics). This finding suggests additional clinical research is needed to understand the association between cannabis use and mental health. The results have implications for patient substance use and mental health–related outcomes. 

Corresponding Author: To contact the corresponding author, Ashley C. Bradford, PhD, email bradford@gatech.edu.

 

(doi:10.1001/jamanetworkopen.2024.32021)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Vision Impairment and the Population Attributable Fraction of Dementia in Older Adults

Posted by Jim Michalski

JAMA Ophthalmology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, SEPTEMBER 5, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.3131?guestAccessKey=26113c66-f05b-4dbc-958d-dbef32ef78a1&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524

 

About The Study: The population attributable fraction of dementia from vision impairments ranged from 4.9%-19.0%. While not proving a cause-and-effect relationship, these findings support inclusion of multiple objective measures of vision impairments, including contrast sensitivity and visual acuity, to capture the total potential impact of addressing vision impairment on dementia. 

Corresponding Author: To contact the corresponding author, Jason R. Smith, ScM, email jsmit491@jhu.edu.

 

(doi:10.1001/jamaophthalmol.2024.3131)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Balloon Angioplasty vs Medical Management for Intracranial Artery Stenosis

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, SEPTEMBER 5, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.12829?guestAccessKey=7352138b-613f-4f16-bba9-75c9e6a7f2b7&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090524

 

About The Study: In patients with symptomatic intracranial atherosclerotic stenosis, balloon angioplasty plus aggressive medical management, compared with aggressive medical management alone, statistically significantly lowered the risk of a composite outcome of any stroke or death within 30 days or an ischemic stroke or revascularization of the qualifying artery after 30 days through 12 months. The findings suggest that balloon angioplasty plus aggressive medical management may be an effective treatment for symptomatic intracranial atherosclerotic stenosis, although the risk of stroke or death within 30 days of balloon angioplasty should be considered in clinical practice.

Corresponding Authors: To contact the corresponding authors, email Zhongrong Miao, MD, PhD (zhongrongm@163.com) and Yilong Wang, MD, PhD (yilong528@aliyun.com).

 

(doi:10.1001/jama.2024.12829)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Risk of Suicide Across Medical Conditions and the Role of Prior Mental Disorder

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.2561?guestAccessKey=c3e67ecc-75ee-4e7a-be90-870f0cb5a479&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090424

No Comments

Filed under:

Lesion-Level Effects of LDL-C–Lowering Therapy in Patients With Acute Myocardial Infarction

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 4:40 A.M. (ET), MONDAY, SEPTEMBER 2, 2024

Media advisory: The full study and commentary are linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.3200?guestAccessKey=1508c832-690b-4b0d-9d00-2a20c1e533dc&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090224

 

About The Study: At the lesion level, very intensive lipid-lowering therapy induced substantially greater percent atheroma volume regression than described in previous vessel-level analyses. Compared with statin therapy alone, alirocumab treatment was associated with greater enlargement of the lesion minimum lumen area and more frequent transition of presumably high-risk plaque phenotypes into more stable, less lipid-rich plaque phenotypes. 

Corresponding Author: To contact the corresponding author, Lorenz Raber, MD, PhD, email lorenz.raeber@insel.ch.

 

(doi:10.1001/jamacardio.2024.3200)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

RSV Vaccine Effectiveness Against Hospitalization Among US Adults 60 Years and Older

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, SEPTEMBER 4, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.15775?guestAccessKey=dfb25f12-9807-4bf4-a8f8-3613f94cf097&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090424

 

About The Study: Among adults age 60 years and older in 19 U.S. states, respiratory syncytial virus (RSV) vaccination was associated with a reduced likelihood of hospitalization with RSV compared with no vaccination. These findings expand upon prelicensure trial results in 2 ways. First, they provide evidence of vaccine protection against RSV-associated hospitalization, of which an estimated 60,000 to 160,000 occur annually among U.S. adults age 65 years and older. Second, they demonstrate protection in a population that more closely represents those at high risk of severe RSV disease, including adults age 75 years and older and those with immunocompromising conditions.

Corresponding Author: To contact the corresponding author, Diya Surie, MD, email dsurie@cdc.gov.

 

(doi:10.1001/jama.2024.15775)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Sex and Size Disparities in Access to Liver Transplant for Patients With Hepatocellular Carcinoma

Posted by Jim Michalski

JAMA Surgery

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, SEPTEMBER 4, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamasurgery/fullarticle/10.1001/jamasurg.2024.3498?guestAccessKey=df6f6278-2b77-43b1-ab49-8e5dfe7a73d0&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090424

 

About The Study: In this study, women with hepatocellular carcinoma were less likely to receive a deceased-donor liver transplant and more likely to die while wait-listed than men with hepatocellular carcinoma; these differences were largely (but not entirely) explained by sex-based differences in candidate size. For candidates listed with exception scores, additional changes to allocation policy are needed to resolve the sex disparity, including solutions to improve access to size-matched donor livers for smaller candidates. 

Corresponding Author: To contact the corresponding author, Heidi Yeh, MD, email hyeh@mgh.harvard.edu.

 

(doi:10.1001/jamasurg.2024.3498)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

State-to-State Variation in Rates and Causes of Child and Adolescent Mortality in the US

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.2894?guestAccessKey=87a95e18-8234-45f5-82b6-e3021e141f3b&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090324

No Comments

Filed under:

Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:00 A.M. ET, MONDAY, SEPTEMBER 2, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17921?guestAccessKey=1955189f-f7bc-47ad-8270-9c65bbd58c7c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090224

 

About The Study: Pulmonary vein isolation resulted in a statistically significant and clinically important decrease in atrial fibrillation burden at 6 months, with substantial improvements in symptoms and quality of life, compared with a sham procedure.

Corresponding Authors: To contact the corresponding authors, email Rick A. Veasey, MD, (rick.veasey@nhs.net) and Rajdip Dulai, MBBS, (rajdip.dulai.21@ucl.ac.uk)

 

(doi:10.1001/jama.2024.17921)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 4:20 A.M. ET, SATURDAY, AUGUST 31, 2024

Media advisory: The full study and editorial are linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.18080?guestAccessKey=9c2ace9b-e153-4404-810d-308ecfd770d6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083124

 

About The Study: Among Black African adults with uncontrolled hypertension, a low-dose triple-pill protocol achieved better blood pressure lowering and control with good tolerability compared with the standard-care protocol.

Corresponding Author: To contact the corresponding author, Anthony Rodgers, PhD, email arodgers@georgeinstitute.org.

 

(doi:10.1001/jama.2024.18080)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Psychiatric Safety of Semaglutide for Weight Management in People Without Known Major Psychopathology

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 3, 2024

Media advisory: The full study and editor’s note are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.4346?guestAccessKey=f3c34dad-e547-4b48-8810-a9af3ea914cb&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090324

 

About The Study: The results of this post hoc analysis suggest that treatment with semaglutide, 2.4 mg, did not increase the risk of developing symptoms of depression or suicidal ideation/behavior vs placebo and was associated with a small but statistically significant reduction in depressive symptoms (not considered clinically meaningful). People with obesity should be monitored for mental health concerns so they can receive appropriate support and care. 

Corresponding Author: To contact the corresponding author, Thomas A. Wadden, PhD, email wadden@pennmedicine.upenn.edu.

 

(doi:10.1001/jamainternmed.2024.4346)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

GLP-1 Receptor Agonist Use and Risk of Suicide Death

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, SEPTEMBER 3, 2024

Media advisory: The full study and editor’s note are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.4369?guestAccessKey=2dc15077-db5b-45cf-b2f1-f1fcf6020c5c&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090324

 

About The Study: This cohort study, including mostly patients with type 2 diabetes, does not show an association between use of glucagon-like peptide-1 (GLP-1) receptor agonists and an increased risk of suicide death, self-harm, or incident depression and anxiety-related disorders.

Corresponding Author: To contact the corresponding author, Peter Ueda, MD, PhD, email peter.ueda@ki.se.

 

(doi:10.1001/jamainternmed.2024.4369)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Effects of Sacubitril/Valsartan on All-Cause Hospitalizations in Heart Failure

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 3 A.M. (ET), FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.2566?guestAccessKey=b53acde0-0218-4ca5-9bbd-2c1b1a51d0c3&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083024

 

About The Study: In this post hoc pooled analysis of 13,194 patients with chronic heart failure (HF) in the PARADIGM-HF and PARAGON-HF randomized clinical trials, sacubitril/valsartan significantly reduced hospitalization for any reason, with benefits most apparent in patients with a left ventricular ejection fraction below normal. This reduction appeared to be principally driven by lower rates of cardiac and pulmonary hospitalizations.

Corresponding Author: To contact the corresponding author, Muthiah Vaduganathan, MD, MPH, email mvaduganathan@bwh.harvard.edu.

 

(doi:10.1001/jamacardio.2024.2566)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prehospital Pulse-Dose Glucocorticoid in ST-Segment Elevation Myocardial Infarction

Posted by Jim Michalski

JAMA Cardiology

EMBARGOED FOR RELEASE: 4 A.M. (ET), FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamacardiology/fullarticle/10.1001/jamacardio.2024.2298?guestAccessKey=a0145eff-4cd6-44be-ae67-9c736ee0ef94&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083024

 

About The Study: In patients with ST-segment elevation myocardial infarction, treatment with prehospital pulse-dose glucocorticoid did not reduce final infarct size after 3 months. However, the trial was likely underpowered as the final infarct size was smaller than anticipated. The glucocorticoid group had improved acute parameters compared with placebo.

Corresponding Author: To contact the corresponding author, Jasmine Melissa Madsen, MD, email jasmine.melissa.madsen.01@regionh.dk.

 

(doi:10.1001/jamacardio.2024.2298)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Potassium Supplementation and Prevention of Atrial Fibrillation After Cardiac Surgery

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12 P.M. ET, SATURDAY, AUGUST 31, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17888?guestAccessKey=dc3f4dcc-6e4a-4a14-b6ad-949ce4c0899f&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083124

 

About The Study: For atrial fibrillation after cardiac surgery prophylaxis, supplementation only when serum potassium concentration fell below 3.6 mEq/L was noninferior to the current widespread practice of supplementing potassium to maintain a serum potassium concentration greater than or equal to 4.5 mEq/L. The lower threshold of supplementation was not associated with any increase in dysrhythmias or adverse clinical outcomes.

Corresponding Author: To contact the corresponding author, Benjamin O’Brien, MD, PhD, email Ben.OBrien@dhzc-charite.de.

 

(doi:10.1001/jama.2024.17888)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Autoimmune Sequelae After Delta or Omicron Variant SARS-CoV-2 Infection in a Highly Vaccinated Cohort

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30983?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cohort study observed no significantly elevated long-term risk of autoimmune sequelae after SARS-CoV-2 Delta and Omicron BA.1 or BA.2 variant infection, except for a modestly increased risk of inflammatory bowel disease and bullous skin disorders in the hospitalized subgroup during the predominance of the Omicron variant. Booster vaccination appeared to mitigate the risk of long-term autoimmune sequelae. 

Corresponding Author: To contact the corresponding author, Liang En Wee, MPH, email ian.wee.l.e@singhealth.com.sg.

 

(doi:10.1001/jamanetworkopen.2024.30983)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Disparate Patient Advocacy When Facing Unaffordable and Problematic Medical Bills

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama-health-forum/fullarticle/10.1001/jamahealthforum.2024.2744?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083024

About JAMA Health Forum: JAMA Health Forum is an international, peer-reviewed, online, open access journal that addresses health policy and strategies affecting medicine, health and health care. The journal publishes original research, evidence-based reports and opinion about national and global health policy; innovative approaches to health care delivery; and health care economics, access, quality, safety, equity and reform. Its distribution will be solely digital and all content will be freely available for anyone to read.

No Comments

Filed under:

Racial Disparities in Cancer Stage at Diagnosis and Survival for Adolescents and Young Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30975?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study suggest that racial disparities in cancer stage at diagnosis and survival exist among adolescent and young adult patients when disaggregated according to federal guidelines, which has health policy and funding implications. These results support the need for tailored interventions and informed public policy to achieve cancer care equity for all races. 

Corresponding Author: To contact the corresponding author, Kekoa Taparra, MD, PhD, email ktaparra@stanford.edu.

 

(doi:10.1001/jamanetworkopen.2024.30975)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Structural Equality and Support Index in Early Childhood Education

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.32050?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=083024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: This cohort study found that early childhood programming is associated with social determinants of health in adulthood. These findings reinforce the importance of early childhood education in addressing health disparities and contributing to healthier, more equitable communities and suggest that educational attainment is a key mechanism for health promotion.

Corresponding Author: To contact the corresponding author, Arthur J. Reynolds, PhD, email ajr@umn.edu.

 

(doi:10.1001/jamanetworkopen.2024.32050)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Continuation vs Discontinuation of Renin-Angiotensin System Inhibitors Before Major Noncardiac Surgery

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 6:45 A.M. ET, FRIDAY, AUGUST 30, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the European Society of Cardiology Congress 2024.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.17123?guestAccessKey=a9f8f5ad-deed-423b-b4a8-e20edbe38c37&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=083024

 

About The Study: Among patients who underwent major noncardiac surgery, a continuation strategy of renin-angiotensin system inhibitors before surgery was not associated with a higher rate of postoperative complications than a discontinuation strategy.

Corresponding Authors: To contact the corresponding authors, email Matthieu Legrand, MD, PhD (matthieu.legrand@ucsf.edu) and Etienne Gayat, MD, PhD (etienne.gayat@aphp.fr).

 

(doi:10.1001/jama.2024.17123)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Greenhouse Gas Emissions and Costs of Inhaler Devices in the US

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.15331?guestAccessKey=6e01fed7-17c7-4ce6-afa8-d5aa732cd02a&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082924

 

About The Study: Inhaler prescriptions filled by Centers for Medicare & Medicaid Services beneficiaries in 2022 resulted in an estimated 1.15 million metric tons of carbon dioxide equivalent emissions, equivalent to 226,960 homes’ yearly electricity use. Metered-dose inhalers were responsible for nearly all inhaler-related emissions, with the largest contribution arising from short-acting β-agonist medications. Although dry-powder and soft-mist inhalers had substantially lower emissions, they accounted for a disproportionate amount of spending, representing nearly two-thirds of inhaler costs but only one-third of claims.

Corresponding Author: To contact the corresponding author, Jyothi Tirumalasetty, MD, email jtsetty@stanford.edu.

 

(doi:10.1001/jama.2024.15331)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Persistent Neighborhood Poverty and Breast Cancer Outcomes

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.27755?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: The findings of this study of women ages 18 or older diagnosed with stage I to III breast cancer between 2010 and 2018 suggest that residing in persistently impoverished neighborhoods is associated with poor tumor characteristics and increased mortality. 

Corresponding Author: To contact the corresponding author, Samilia Obeng-Gyasi, MD, MPH, email samilia.obeng-gyasi@osumc.edu.

 

(doi:10.1001/jamanetworkopen.2024.27755)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Hormone Therapy and Biological Aging in Postmenopausal Women

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 29, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30839?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Postmenopausal women with historical hormone therapy (HT) use were biologically younger than those not receiving HT, with a more evident association observed in those with low socioeconomic status. The biological aging discrepancy mediated the association between HT and decreased mortality. Promoting HT in postmenopausal women could be important for healthy aging.

Corresponding Author: To contact the corresponding author, Chenglong Li, PhD, email chenglongli@bjmu.edu.cn.

 

(doi:10.1001/jamanetworkopen.2024.30839)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamadermatology/fullarticle/10.1001/jamadermatol.2024.2849?guestAccessKey=6d747043-45eb-4645-bb2e-b4998c41d7f6&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082824

No Comments

Filed under:

First-Generation Antihistamines and Seizures in Young Children

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, AUGUST 28, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29654?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Prescriptions for first-generation antihistamines were associated with a 22.0% higher seizure risk in children, especially in those ages 6 to 24 months in this cohort study. These findings emphasize the need for careful and judicious prescription of first-generation antihistamines in young children and underline the need for further research to elucidate associations between antihistamine prescriptions and seizure risk.

Corresponding Authors: To contact the corresponding authors, email Seonkyeong Rhie, MD, (starclusters@gmail.com) and Man Yong Han, MD, (drmesh@gmail.com).

 

(doi:10.1001/jamanetworkopen.2024.29654)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Intersection of Poverty and Rurality for Early-Onset Colorectal Cancer Survival

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, AUGUST 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30615?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082824

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Patients with early-onset colorectal cancer (defined as colorectal cancer diagnosed in individuals younger than 50 years) living in rural areas had lower 5-year survival rates than their urban dwelling counterparts in this study. While it was not observed consistently for all age groups, persistent poverty in these rural areas may compound this association.

Corresponding Author: To contact the corresponding author, Meng-Han Tsai, PhD, metsai@augusta.edu.

 

(doi:10.1001/jamanetworkopen.2024.30615)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Race and Ethnicity and Diagnostic Testing for Common Conditions in the Acute Care Setting

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, AUGUST 27, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30306?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082724

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: White patients discharged from the emergency department with a nonspecific diagnosis of interest were significantly more likely than Black patients to receive related diagnostic testing in this study. The extent to which this represents diagnostic test overuse in white patients vs undertesting and missed diagnoses in Black patients deserves further study. 

Corresponding Author: To contact the corresponding author, Michael I. Ellenbogen, M.D., email mellenb6@jhmi.edu.

 

(doi:10.1001/jamanetworkopen.2024.30306)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Thirty-Year Trends in Perioperative Mortality Risk for Living Kidney Donors

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, AUGUST 28, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.14527?guestAccessKey=c2c796f4-1583-4ebc-b6b7-0514806dcb62&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082824

 

About The Study: Perioperative mortality after living donation declined substantially in the past decade compared with prior decades, to fewer than 1 event per 10,000 donations. Risk was higher for male donors and donors with a history of hypertension. Current guidelines for donor informed consent, based on 2009 data, should be updated to reflect this information.

Corresponding Author: To contact the corresponding author, Dorry L. Segev, MD, PhD, email dorry.segev@nyulangone.org.

 

(doi:10.1001/jama.2024.14527)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Breast Cancer Screening Using Mammography, Digital Breast Tomosynthesis, and MRI by Breast Density

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.4224?guestAccessKey=42331c3b-2f72-4d7b-80a9-39cddc1a34f6&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624

No Comments

Filed under:

Transgender Adolescent School Climate, Mental Health, and Adult Social Support

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.3079?guestAccessKey=6d53b200-3832-4d11-9929-a2f412cce3e2&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624

No Comments

Filed under:

Long-Term Prognosis of Patients With Myocarditis Attributed to COVID-19 mRNA Vaccination, SARS-CoV-2 Infection, or Conventional Etiologies

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 3 P.M. ET, MONDAY, AUGUST 26, 2024

Media advisory: The full study is linked to this news release. This study is being presented at the 2024 International Society for Pharmacoepidemiology Annual Meeting.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.16380?guestAccessKey=07ee8e37-54d7-4436-8659-20e806e46c32&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624

 

About The Study: Patients with post–COVID-19 mRNA vaccination myocarditis, contrary to those with post–COVID-19 myocarditis, show a lower frequency of cardiovascular complications than those with conventional myocarditis at 18 months. However, affected patients, mainly healthy young men, may require medical management up to several months after hospital discharge.

Corresponding Authors: To contact the corresponding authors, email Laura Semenzato, MSc (laura.semenzato@assurance-maladie.fr) and Mahmoud Zureik, MD, PhD (Mahmoud.ZUREIK@ansm.sante.fr).

 

(doi:10.1001/jama.2024.16380)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Longitudinal Changes in Youth Mental Health From Before to During the COVID-19 Pandemic

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, AUGUST 26, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.30198?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this longitudinal cohort study of economically and racially diverse U.S. youth, there was evidence of differential susceptibility and resilience for mental health problems during the pandemic that was associated with prepandemic mental health and sociodemographic characteristics. These differences are critical to understand for recovery and may yield novel insights into causes of youth mental health problems. 

Corresponding Authors: To contact the corresponding authors, email Courtney K. Blackwell, PhD (ckblackwell@northwestern.edu) and Kaja Z. LeWinn, ScD (kaja.lewinn@ucsf.edu).

 

(doi:10.1001/jamanetworkopen.2024.30198)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Repetitive Head Impacts and Perivascular Space Volume in Former Football Players

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, AUGUST 26, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.28687?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082624

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional cohort study of 170 former football players and 54 unexposed controls, larger perivascular space (PVS) volume was associated with greater exposure to repetitive head impacts (RHI). Additionally, PVS volume was associated with worse performance on cognitive tests. These findings suggest that PVS volume may contribute to the association between exposure to RHI, cognitive impairment, and the development of RHI-associated neurodegeneration. 

Corresponding Author: To contact the corresponding author, Inga K. Koerte, MD, PhD, email ikoerte@bwh.harvard.edu.

 

(doi:10.1001/jamanetworkopen.2024.28687)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Neighborhood-Level Disparities in Hypertension Prevalence and Treatment Among Middle-Aged Adults

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, FRIDAY, AUGUST 23, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29764?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082324

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Researchers found corresponding increases in hypertension prevalence as neighborhood disadvantage and the percentage of Black patients residing in a neighborhood increased in this cross-sectional study. A higher burden of midlife hypertension was identified in Black adults compared with other racial and ethnic groups that persisted across levels of socioeconomic disadvantage. This study also found that living in socioeconomically disadvantaged neighborhoods was associated with higher hypertension rates among people of all racial and ethnic backgrounds. Using spatial analysis techniques to identify neighborhoods in need, future research might investigate structural interventions to address place-based hypertension disparities. 

Corresponding Author: To contact the corresponding author, Jarrod E. Dalton, PhD, email daltonj@ccf.org.

 

(doi:10.1001/jamanetworkopen.2024.29764)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trends of Heat-Related Deaths in the US, 1999-2023

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, AUGUST 26, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.16386?guestAccessKey=53b50a89-0945-4117-a662-5e1e1484ebce&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082624

 

About The Study: This study found that heat-related mortality rates in the U.S. increased between 1999 and 2023, especially during the last 7 years. Although a study using data through 2018 found a downward trend in heat-related mortality in the U.S., this study is the first to our knowledge to demonstrate a reversal of this trend from 2016 to 2023. These results align with site-specific data analyzed in a global study that suggest increases in heat-related mortality. As temperatures continue to rise because of climate change, the recent increasing trend is likely to continue. Local authorities in high-risk areas should consider investing in the expansion of access to hydration centers and public cooling centers or other buildings with air conditioning.

Corresponding Author: To contact the corresponding author, Jeffrey T. Howard, PhD, email jeffrey.howard@utsa.edu.

 

(doi:10.1001/jama.2024.16386)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

A Screening Strategy to Mitigate Vision Impairment by Engaging Adults Who Underuse Eye Care Services

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2024.3132?guestAccessKey=1a443f06-07ee-454c-b4c0-e1d67e0fdd7d&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082224

No Comments

Filed under:

Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 22, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.14618?guestAccessKey=79b5ac8d-500e-4ab7-9d91-d90baedd6140&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082224

 

About The Study: In two pivotal phase 3 clinical trials, elinzanetant, a selective neurokinin-1,3 receptor antagonist, demonstrated statistically significant reductions in vasomotor symptoms (VMS) frequency and severity vs placebo in postmenopausal individuals with moderate to severe VMS. Elinzanetant also significantly improved sleep disturbances and menopause-related quality of life vs placebo; the safety profile was favorable.

Corresponding Author: To contact the corresponding author, JoAnn V. Pinkerton, MD, MSCP, email JVP9U@uvahealth.org.

 

(doi:10.1001/jama.2024.14618)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Disparities in Exposure to Tobacco on Television or Streaming Platforms

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.27781?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this study of the prevalence of exposure to tobacco advertisements on TV or streaming platforms among U.S. adults, disparities in exposure by race or ethnicity, education level, and smoking status were identified. These findings underscore the need for targeted public health interventions and regulation to address these disparities and reduce the impact of tobacco advertisements on vulnerable populations. 

Corresponding Author: To contact the corresponding author, Sanjay Shete, PhD, email sshete@mdanderson.org.

 

(doi:10.1001/jamanetworkopen.2024.27781)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Trends in Children’s Exposure to Food and Beverage Advertising on Television

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, THURSDAY, AUGUST 22, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29671?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082224

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

  

About The Study: In this repeated cross-sectional study of children’s exposure to food-related television advertisements, exposure via children’s programming decreased substantially. However, most advertisements seen were still for unhealthy products, and exposure from all programming remained substantial. Findings of more than 90% of advertising exposure not from children’s programming and more than 1,000 food-related advertisements seen per year suggest the need for government regulations based on time of day rather than programming. 

Corresponding Author: To contact the corresponding author, Lisa M. Powell, PhD, email powelll@uic.edu.

 

(doi:10.1001/jamanetworkopen.2024.29671)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Virtual Learning in Kindergarten Through Grade 12 During the COVID-19 Pandemic and Chronic Absenteeism

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, WEDNESDAY, AUGUST 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29569?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082124

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: Chronic absenteeism rates were substantially higher in school districts that used virtual learning during the COVID-19 pandemic compared with in person in this cross-sectional study. Understanding how to reduce chronic absenteeism and use virtual learning without potentially negative consequences are key policy questions moving forward. 

Corresponding Author: To contact the corresponding author, William N. Evans, PhD, email wevans1@nd.edu.

 

(doi:10.1001/jamanetworkopen.2024.29569)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

COVID-19 and Mental Illnesses in Vaccinated and Unvaccinated People

Posted by Jim Michalski

JAMA Psychiatry

EMBARGOED FOR RELEASE: 11 A.M. (ET), WEDNESDAY, AUGUST 21, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapsychiatry/fullarticle/10.1001/jamapsychiatry.2024.2339?guestAccessKey=0295d46c-9ecf-4656-8832-f43a5024d785&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082124

 

About The Study: In this cohort study, depression, serious mental illness, general anxiety, posttraumatic stress disorder, eating disorders, addiction, self-harm, and suicide were elevated during weeks 1 through 4 after COVID-19 diagnosis compared with before or without COVID-19. Incidence was lower in people who were vaccinated when they had COVID-19 and incidence was higher, and persisted longer, after hospitalization for COVID-19. The findings support recommendation of COVID-19 vaccination in the general population and particularly among those with mental illness, who may be at higher risk of both SARS-CoV-2 infection and adverse outcomes following COVID-19.

  

Quote from co-author Venexia M. Walker, PhD:

“Our findings have important implications for public health and mental health service provision, as serious mental illnesses are associated with more intensive healthcare needs and longer-term health and other adverse effects.

“Our results highlight the importance COVID-19 vaccination in the general population and particularly among those with mental illnesses, who may be at higher risk of both SARS-CoV-2 infection and adverse outcomes following COVID-19.”

 

Contact information for corresponding author Jonathan Sterne, PhD: email press-office@bristol.ac.uk.

 

(10.1001/jamapsychiatry.2024.2339)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Characterizing Long COVID in Children and Adolescents

Posted by Jim Michalski

JAMA

EMBARGOED FOR RELEASE: 12 P.M. ET, WEDNESDAY, AUGUST 21, 2024

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2024.12747?guestAccessKey=bbe06786-8f16-435f-a2b4-bb71986c6ccc&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=082124

 

About The Study: In this large-scale study, symptoms that characterized pediatric postacute sequelae of SARS-CoV-2 infection (PASC), or long COVID, differed by age group, and several distinct phenotypic PASC presentations were described. The research indices developed here will help researchers identify children and adolescents with high likelihood of PASC. Although these indices will require further research and validation, this work provides an important step toward a clinically useful tool for diagnosis with the ultimate goal of supporting optimal care for youth with PASC.

 

Quote from corresponding author Rachel S. Gross, MD, MS:

“Our study is one of the first of its kind to characterize long COVID symptoms in children across age groups and develop a tool to help identify those who are most likely to have long COVID. This is important because there remains a common misperception that pediatric long COVID is rare, and this research can raise awareness of its impact on children.

“For this study, we looked at different groupings of symptoms across varying childhood ages and found that many of the symptoms were similar, but distinguishable from each other. Understanding why these differences occur can help inform future treatment tailored for specific age groups.”

 

Contact information for Rachel S. Gross, MD, MS: email Domonique Chaplin at Domonique.Chaplin@nyulangone.org.

 

(doi:10.1001/jama.2024.12747)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Individual- and Community-Level Risk Factors of Cancer-Related Financial Hardship Among Cancer Survivors

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, AUGUST 20, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29286?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this cross-sectional study, approximately 50% of cancer survivors experienced cancer-related financial hardship, with a disproportionate number of survivors who were younger, were Medicare or Medicaid beneficiaries, were socioeconomically disadvantaged, and had advanced disease. Social vulnerability was independently associated with increasing levels of financial hardship, emphasizing the central role one’s community may play in cancer survivorship and the compounding financial detriments of residing in a socially vulnerable community. 

Corresponding Author: To contact the corresponding author, Rishi Robert Sekar, MD, MS, email rsekar@med.umich.edu.

 

(doi:10.1001/jamanetworkopen.2024.29286)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, TUESDAY, AUGUST 20, 2024

Media advisory: The full study and commentary are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.23385?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=082024

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

 

About The Study: In this disproportionality study of an adverse drug reaction database, researchers identified a disproportionality signal of suicidal ideation with semaglutide, but not for liraglutide, particularly among patients with co-reported antidepressant use, a proxy for affective disorders (a notable exclusion criteria of premarketing clinical trials). A detected signal of semaglutide-associated suicidal ideation warrants urgent clarification. 

Corresponding Author: To contact the corresponding author, Georgios Schoretsanitis, MD, PhD, email george.schor@gmail.com.

 

(doi:10.1001/jamanetworkopen.2024.23385)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Time to Gender-Affirming Hormone Therapy Among US Military–Affiliated Adolescents and Young Adults

Posted by Jim Michalski

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2024.2835?guestAccessKey=42c6a28e-e567-419c-a41d-e8e03a2795cd&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081924

No Comments

Filed under:

Expanded Child Tax Credit and Food Insecurity

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, AUGUST 19, 2024

Media advisory: The full study is linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.3972?guestAccessKey=617d31a7-1205-407d-a766-f3ddf2659414&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081924

 

About The Study: Expanded Child Tax Credit (ECTC) enactment was associated with substantially lower food insecurity, and ECTC expiration was associated with substantially greater food insecurity in this cohort study. Key features of the ECTC—monthly payments and no earnings requirements—may be important for food insecurity prevention. Future studies should examine this, along with income as a potential effect modifier. 

Corresponding Author: To contact the corresponding author, Seth A. Berkowitz, MD, MPH, email seth_berkowitz@med.unc.edu.

 

(doi:10.1001/jamainternmed.2024.3972)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Telehealth Mindfulness-Based Interventions for Chronic Pain

Posted by Jim Michalski

JAMA Internal Medicine

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, AUGUST 19, 2024

Media advisory: The full study and commentary are linked to this news release.  

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/jamainternmed.2024.3940?guestAccessKey=bc2cb3b5-b6de-44a4-a6d2-478de3d8c145&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=081924

 

About The Study: Scalable telehealth mindfulness-based interventions improved pain-related function and biopsychosocial outcomes compared to usual care among veterans with chronic pain in this randomized clinical trial. Relatively low-resource telehealth-based mindfulness-based interventions could help accelerate and improve the implementation of nonpharmacological pain treatment in health care systems.

Corresponding Author: To contact the corresponding author, Diana J. Burgess, PhD, email diana.burgess@va.gov.

 

(doi:10.1001/jamainternmed.2024.3940)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under:

Machine Learning Prediction of Autism Spectrum Disorder From a Minimal Set of Medical and Background Information

Posted by Jim Michalski

JAMA Network Open

EMBARGOED FOR RELEASE: 11 A.M. ET, MONDAY, AUGUST 19, 2024

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.29229?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=081924

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication.

  

About The Study: The machine learning model developed in this study shows promise in the early identification of individuals with an elevated likelihood of autism spectrum disorder, using minimal information, which could affect early diagnosis and intervention strategies. 

Corresponding Author: To contact the corresponding author, Kristiina Tammimies, PhD, email kristiina.tammimies@ki.se.

 

(doi:10.1001/jamanetworkopen.2024.29229)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.

No Comments

Filed under: